First-in-Human Study of Orally Administered GS-441524 for COVID-19

Completed · Phase 1

Conditions studied: COVID-19

In brief

This is a two-part study is to evaluate the multi-day safety, tolerability, and pharmacokinetics (PK) of orally administered GS-441524 in a healthy human volunteer.

Key facts

Study ID

NCT04859244

Run by

Copycat Sciences LLC

People needed

1

Starts

2021-01-01

Expected to finish

2021-08-01

Last updated by the study team

2021-08-10

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: accepted.

You may qualify if…

• Willing and able to provide written informed consent
• Negative pregnancy test at screening and prior to dosing
• Minimum body weight of 50 kg and body mass index (BMI) of 18-32 kg/m2

You may not qualify if…

• Use of other investigational drugs within 28 days of dosing
• Positive pregnancy test
• Abuse of alcohol or drugs
• Other clinically significant medical conditions or laboratory abnormalities

Where it is running

• Copycat Sciences Study Site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.